EP1326627A4 - Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine - Google Patents

Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine

Info

Publication number: EP1326627A4
Authority: EP; European Patent Office
Prior art keywords: antagonists; administration; methods; modulating apoptosis; relaxin agonists
Prior art date: 2000-10-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP01979945A

Other languages

German (de)

English (en)

Other versions

EP1326627A1 (fr

Inventor

Edward P Amento

Chrishan S Samuel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Molecular Medicine Research Institute

Original Assignee

Molecular Medicine Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-04

Filing date

2001-10-04

Publication date

2004-06-16

2001-10-04 Application filed by Molecular Medicine Research Institute filed Critical Molecular Medicine Research Institute

2003-07-16 Publication of EP1326627A1 publication Critical patent/EP1326627A1/fr

2004-06-16 Publication of EP1326627A4 publication Critical patent/EP1326627A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Zoology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)

EP01979945A 2000-10-04 2001-10-04 Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine Withdrawn EP1326627A4 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US23823200P	2000-10-04	2000-10-04
US238232P		2000-10-04
US24203700P	2000-10-20	2000-10-20
US24199100P	2000-10-20	2000-10-20
US242037P		2000-10-20
US241991P		2000-10-20
PCT/US2001/042484 WO2002028418A1 (fr)	2000-10-04	2001-10-04	Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine

Publications (2)

Publication Number	Publication Date
EP1326627A1 EP1326627A1 (fr)	2003-07-16
EP1326627A4 true EP1326627A4 (fr)	2004-06-16

Family

ID=27399064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP01979945A Withdrawn EP1326627A4 (fr)	2000-10-04	2001-10-04	Methodes de modulation de l'apoptose par l'administration d'agonistes ou d'antagonistes de relaxine

Country Status (7)

Country	Link
EP (1)	EP1326627A4 (fr)
JP (3)	JP2004510743A (fr)
AU (2)	AU1185502A (fr)
CA (2)	CA2425712C (fr)
IL (1)	IL155250A0 (fr)
NZ (1)	NZ525389A (fr)
WO (1)	WO2002028418A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040006205A1 (en) *	2001-04-03	2004-01-08	Li Li	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2006110743A1 (fr)	2005-04-07	2006-10-19	Cardiopep Pharma Gmbh	Utilisation de peptide natriuretique pour le traitement d'une insuffisance cardiaque
WO2007115414A1 (fr) *	2006-04-11	2007-10-18	University Of Guelph	Relaxine h2 modifiée pour la suppression de tumeurs
KR20110099762A (ko) *	2008-12-26	2011-09-08	고쿠리츠다이가쿠호우진 도쿄다이가쿠	항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
ES2968649T3 (es) *	2012-12-07	2024-05-13	Translate Bio Inc	Nanopartículas lipídicas para la administración de ARNm en los pulmones
CA2898571A1 (fr) *	2013-01-25	2014-07-31	Cardiorentis Ltd.	Methodes de traitement d'indications cardiovasculaires
CN113147632B (zh) *	2021-05-17	2023-03-07	中国第一汽车股份有限公司	一种车辆控制方法、装置、车辆及存储介质

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH661662A5 (en) *	1984-04-16	1987-08-14	Georg L Prof Dr Floersheim	Product for the treatment of the skin and of the connective tissue
WO1994029452A2 (fr) *	1993-06-09	1994-12-22	Ribozyme Pharmaceuticals, Inc.	Molecule d'arn enzymatique pour le traitement de la fibrose et de la maladie du tissu fibreux
WO1995007711A1 (fr) *	1993-09-14	1995-03-23	Mallinckrodt Medical, Inc.	Traitement therapeutique destine a inhiber l'obstruction des vaisseaux sanguins a l'aide d'un polypeptide
WO1999040929A1 (fr) *	1998-02-12	1999-08-19	The General Hospital Corporation	Procedes de potentialisation des cancerotherapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811395A (en) *	1995-06-07	1998-09-22	Medical University Of South Carolina	Relaxin analogs and derivatives methods and uses thereof

2001
- 2001-10-04 JP JP2002532242A patent/JP2004510743A/ja not_active Withdrawn
- 2001-10-04 CA CA2425712A patent/CA2425712C/fr not_active Expired - Lifetime
- 2001-10-04 CA CA2967607A patent/CA2967607A1/fr not_active Abandoned
- 2001-10-04 EP EP01979945A patent/EP1326627A4/fr not_active Withdrawn
- 2001-10-04 AU AU1185502A patent/AU1185502A/xx active Pending
- 2001-10-04 WO PCT/US2001/042484 patent/WO2002028418A1/fr not_active Ceased
- 2001-10-04 IL IL15525001A patent/IL155250A0/xx unknown
- 2001-10-04 NZ NZ525389A patent/NZ525389A/en not_active IP Right Cessation
- 2001-10-04 AU AU2002211855A patent/AU2002211855B2/en not_active Ceased
2008
- 2008-07-25 JP JP2008192676A patent/JP2008297313A/ja not_active Withdrawn
2012
- 2012-07-06 JP JP2012152837A patent/JP2012184273A/ja active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH661662A5 (en) *	1984-04-16	1987-08-14	Georg L Prof Dr Floersheim	Product for the treatment of the skin and of the connective tissue
WO1994029452A2 (fr) *	1993-06-09	1994-12-22	Ribozyme Pharmaceuticals, Inc.	Molecule d'arn enzymatique pour le traitement de la fibrose et de la maladie du tissu fibreux
WO1995007711A1 (fr) *	1993-09-14	1995-03-23	Mallinckrodt Medical, Inc.	Traitement therapeutique destine a inhiber l'obstruction des vaisseaux sanguins a l'aide d'un polypeptide
WO1999040929A1 (fr) *	1998-02-12	1999-08-19	The General Hospital Corporation	Procedes de potentialisation des cancerotherapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0228418A1 *

Also Published As

Publication number	Publication date
EP1326627A1 (fr)	2003-07-16
CA2425712A1 (fr)	2002-04-11
WO2002028418A1 (fr)	2002-04-11
JP2004510743A (ja)	2004-04-08
JP2008297313A (ja)	2008-12-11
AU1185502A (en)	2002-04-15
CA2967607A1 (fr)	2002-04-11
NZ525389A (en)	2009-04-30
WO2002028418B1 (fr)	2002-07-18
AU2002211855B2 (en)	2007-06-07
CA2425712C (fr)	2017-06-06
IL155250A0 (en)	2003-11-23
JP2012184273A (ja)	2012-09-27

Publication	Publication Date	Title
EE200300246A (et)	2003-10-15	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
IS6388A (is)	2002-05-17	EP4 viðtaka valvís gerandefni í meðhöndluninni á beingisnun
NO20032797L (no)	2003-08-19	Substituerte pyridoindoler som serotonin agonister og antagonister
NO20013183D0 (no)	2001-06-25	Azabicykloalkaner som CCR5-modulatorer
LTC1284974I2 (lt)	2020-11-10	Triazoliltropano dariniai kaip CCR5 moduliatoriai
CY2013011I2 (el)	2015-08-05	Μεθοδος χορηγησης διφωσφονικων
MXPA02008402A (es)	2003-10-14	Derivados de quinolina como antagonistas alfa-2.
PL357780A1 (en)	2004-07-26	Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain
PL350347A1 (en)	2002-05-06	Method of obtaining non-steroidic modulators of the glucosteroid receptor
ZA200305803B (en)	2004-07-28	Prevention of diabetes by administration of GnRH antagonists.
AU1185502A (en)	2002-04-15	Methods of modulating apoptosis by administration of relaxin agonists or antagonists
ZA200109206B (en)	2003-05-28	Preparation of substituted piperidin-4-ones.
ZA200201521B (en)	2003-05-22	Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
MXPA03005405A (es)	2003-09-25	Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
ITMI20000050A0 (it)	2000-01-18	Procedimento per la preparazione della 5-carbossiftalide
AU2002216245A1 (en)	2002-07-08	Methods of modulating toll-related receptor (trr) signaling
AU3448601A (en)	2001-07-31	Continuous surveyor monitor
DE60023020D1 (de)	2006-02-16	Positive modulatoren von nicotinrezeptor-agonisten
AU2001264900A1 (en)	2001-12-03	Pharmaceutical use of fibulin-1
ZA200309774B (en)	2005-03-17	Methods for preparation and use of psorospermin analogs.
GB0022644D0 (en)	2000-11-01	Antitumoral derivatives of ET-743
SI1282616T1 (en)	2004-10-31	Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain
TW376154U (en)	1999-12-01	Laser level of multi-angle directions
GB0008741D0 (en)	2000-05-31	Administration of beneficial substances
GB0108923D0 (en)	2001-05-30	Administration of beneficial substances

Legal Events

Date	Code	Title	Description
2003-05-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2003-07-16	17P	Request for examination filed	Effective date: 20030430
2003-07-16	AK	Designated contracting states	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2003-07-16	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-06-16	A4	Supplementary search report drawn up and despatched	Effective date: 20040504
2004-06-16	RIC1	Information provided on ipc code assigned before grant	Ipc: 7C 07K 14/64 B Ipc: 7A 61P 35/00 B Ipc: 7A 61K 38/22 B Ipc: 7A 61K 38/17 A
2007-01-10	17Q	First examination report despatched	Effective date: 20051228
2009-10-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2009-11-04	18D	Application deemed to be withdrawn	Effective date: 20090505